An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Inclusion Criteria

• •Male aged ≥19 years
• •Patients with high risk nmCPRC
• •* Castrate level of serum testosterone (\< 1.7 nmol/l \[50 ng/dL\])
• •* PSA doubling time \< 10 months
• •Patients with mHSPC
• •* histologically or cytologically confirmed prostate cancer, and metastases detected on bone scanning, contrast-enhanced computed tomography (CT), or magnetic resonance imaging (MRI).
• •* be candidates for androgen-deprivation therapy with/without docetaxel.
• •Patients for whom the decision to initiate treatment with Darolutamide as a first time was made as per investigator's routine treatment practice
• •Written informed consent from subject or legal representative; assent from subject when appropriate